Tirzepatide lyofilize segondè pite 99% peptides poud tr 10mg 15mg 20mg 30mg pou chak ti poban pou sik nan san/dyabèt

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and under investigation for use in chronic weight management, major adverse cardiovascular events and the management of other conditions, including heart failure with preserved ejection fraction ak obezite ak steatohepatitis ki pa cirrhotic ki pa gen alkòl. Faz 3 surpasser 1-5 pwogram nan esè klinik te fèt yo evalye efikasite ak sekirite nan yon fwa-chak semèn subcutaneously enjeksyon tirzepatide (5, 10 ak 15 mg), kòm monoterapi oswa terapi konbinezon, atravè yon espèk laj nan moun ki gen dyabèt tip 2. Use of tirzepatide in clinical studies was associated with marked reductions of glycated haemoglobin (-1.87 to -2.59%, -20 to -28 mmol/mol) and body weight (-6.2 to -12.9 kg), as well as reductions in parameters commonly associated with heightened cardiometabolic risk such as blood pressure, visceral adiposity and circulating trigliserid. Tirzepatide te byen tolere, ak yon risk ki ba nan ipoglisemi lè yo itilize san ensilin oswa ensilin secretagogues ak te montre yon pwofil sekirite jeneralman menm jan ak klas la agonist reseptè GLP-1. An konsekans, prèv ki soti nan esè sa yo nan klinik sijere ke Tirzepatide ofri yon nouvo opòtinite pou bese a efikas nan emoglobin glycated ak pwa kò nan granmoun ki gen dyabèt tip 2.